These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31132584)

  • 41. Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial.
    Vranckx P; Leebeek FW; Tijssen JG; Koolen J; Stammen F; Herman JP; de Winter RJ; van T Hof AW; Backx B; Lindeboom W; Kim SY; Kirsch B; van Eickels M; Misselwitz F; Verheugt FW
    Thromb Haemost; 2015 Aug; 114(2):258-67. PubMed ID: 25925992
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis.
    Lee J; Nakanishi R; Li D; Shaikh K; Shekar C; Osawa K; Nezarat N; Jayawardena E; Blanco M; Chen M; Sieckert M; Nelson E; Billingsley D; Hamal S; Budoff MJ
    Am Heart J; 2018 Dec; 206():127-130. PubMed ID: 30227941
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
    Prescrire Int; 2014 Oct; 23(153):229-32. PubMed ID: 25964962
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease.
    Willmann S; Ince I; Ahsman M; Coboeken K; Zhang Y; Thelen K; Kubitza D; Zannikos P; Zhou W; Pina LM; Post T; Lippert J
    CPT Pharmacometrics Syst Pharmacol; 2022 Aug; 11(8):1111-1121. PubMed ID: 35665486
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?
    Yates SG; Smith S; Tharpe W; Shen YM; Sarode R
    Transfus Apher Sci; 2016 Oct; 55(2):212-215. PubMed ID: 27377884
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dosing of rivaroxaban by indication: getting the right dose for the patient.
    Escolar G; Carne X; Arellano-Rodrigo E
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1665-77. PubMed ID: 26329812
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Triple therapy: worth the risk?
    Wernly B; Lichtenauer M; Hoppe UC; Lauten A; Navarese EP; Jung C
    Minerva Med; 2018 Oct; 109(5):403-405. PubMed ID: 30338683
    [No Abstract]   [Full Text] [Related]  

  • 48. [Rivaroxaban (Xarelto): efficacy and safety].
    Rosencher N; Arnaout L; Chabbouh T; Bellamy L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S22-7. PubMed ID: 19185784
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
    Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
    Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.
    Yuan J
    BMC Pharmacol Toxicol; 2018 May; 19(1):19. PubMed ID: 29720261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial.
    Nicholls SJ; Nelson AJ
    Am J Cardiovasc Drugs; 2019 Aug; 19(4):343-348. PubMed ID: 30680652
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
    Med Lett Drugs Ther; 2018 Dec; 60(1561):196-197. PubMed ID: 30653475
    [No Abstract]   [Full Text] [Related]  

  • 54. [The COMPASS study].
    Calabrò P; Gragnano F; Visconti LO
    G Ital Cardiol (Rome); 2018 Jan; 19(1):1-7. PubMed ID: 29451504
    [No Abstract]   [Full Text] [Related]  

  • 55. Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
    Weisshaar S; Litschauer B; Gouya G; Mayer P; Smerda L; Kapiotis S; Kyrle PA; Eichinger S; Wolzt M
    J Thromb Haemost; 2014 Nov; 12(11):1850-60. PubMed ID: 25211369
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose-finding study of rivaroxaban in hemodialysis patients.
    De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
    Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rivaroxaban for prevention and treatment of venous thromboembolism.
    Chan NC; Weitz JI
    Future Cardiol; 2019 Mar; 15(2):63-77. PubMed ID: 30779598
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rivaroxaban: an oral direct inhibitor of factor Xa.
    Gulseth MP; Michaud J; Nutescu EA
    Am J Health Syst Pharm; 2008 Aug; 65(16):1520-9. PubMed ID: 18693206
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
    Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
    Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preventing thrombosis after the Fontan procedure not there yet.
    Canter CE
    J Am Coll Cardiol; 2011 Aug; 58(6):652-3. PubMed ID: 21798430
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.